Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
AKESO Receives NMPA Approval for New Indication for Ivonescimab as Treatment for NSCLC
Recommend 2 Positive 3 Negative 2 |
||||
|
||||
|
AKESO (09926.HK) announced the global first-in-class PD-1/VEGF bi-specific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New Drug Application (sNDA) for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS greater than or equal 1%) non-small cell lung cancer (NSCLC) in patients who are negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) gene mutations. This indication marks ivonescimab's second major approval. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
